What are the formulations of Hormone Replacement Therapy (HRT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Hormone replacement therapy (HRT) should be used at the lowest effective dose for the shortest possible time to manage menopausal symptoms, as recommended by expert groups 1.

HRT Formulations

HRT is available in several formulations, including:

  • Oral tablets (such as Premarin, Estrace, or Prempro)
  • Transdermal patches (like Climara or Vivelle-Dot)
  • Topical gels and creams (Estrogel, Divigel)
  • Vaginal preparations (Vagifem tablets, Estring)
  • Injectable options For estrogen therapy, typical doses range from 0.3-1.25mg for oral estradiol, 0.025-0.1mg/day for patches, and 0.5-1.5g daily for gels. Progesterone is often added for women with an intact uterus, commonly as oral micronized progesterone (100-200mg daily) or medroxyprogesterone acetate (2.5-5mg daily) 1.

Choosing an HRT Formulation

The choice between formulations depends on:

  • Symptom profile
  • Risk factors
  • Patient preference Transdermal options bypass first-pass liver metabolism, potentially reducing clotting risks compared to oral formulations 1. Vaginal preparations provide localized relief for urogenital symptoms with minimal systemic absorption.

Treatment Approach

Treatment typically begins at the lowest effective dose and continues as needed for symptom management, with regular monitoring recommended to assess benefits and risks 1. The quality of evidence on the benefits and harms of HRT varies for different hormone regimens, and a cautious approach is recommended to avoid using HRT routinely for the specific purpose of preventing chronic disease in women 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

HRT Formulations

  • Various formulations of Hormone Replacement Therapy (HRT) are available, including testosterone replacement therapy for hypogonadal men 2, 3, 4.
  • The choice of formulation depends on factors such as cost, patient preference, and individual needs 3, 4.
  • Testosterone replacement therapy can be administered through different routes, including buccal, nasal, subdermal, transdermal, and intramuscular (IM) 4.
  • For women, HRT can be formulated with estrogen and progestogen, and the regimen can be cyclical or continuous, depending on the patient's needs and whether they have an intact uterus 5.

Types of HRT

  • Topical gels and intramuscular injections are examples of testosterone formulations available for men 3.
  • Selective estrogen receptor modulators and phytoestrogens are being developed as alternative options for managing menopause symptoms in women 5.
  • Non-hormonal pharmacotherapies are also available for patients who cannot or do not want to use exogenous hormones 3.

Considerations for HRT

  • The use of HRT should be individualized, taking into account the patient's unique characteristics, needs, and goals 3, 6.
  • Patients should be counseled about the risks and benefits of HRT, and their preferences should be considered when selecting a formulation 5, 3.
  • Close monitoring is required for patients receiving HRT to minimize risks and optimize benefits 4, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Testosterone Replacement Therapy in Hypogonadal Men.

Endocrinology and metabolism clinics of North America, 2022

Research

Testosterone replacement therapy.

Andrology, 2020

Related Questions

What are the implications of low testosterone (hypogonadism) levels, specifically less than 3 nanograms per deciliter (ng/dL), in a female?
Should testosterone replacement therapy (TRT) be continued perioperatively?
What are the risks associated with estradiol (Estrogen) and testosterone replacement therapy?
What is the duration of therapy for hypogonadism (low testosterone)?
What are the considerations when a patient asks for exogenous testosterone (testosterone replacement therapy)?
What is the role of Hormone Replacement Therapy (HRT) for managing perimenopausal symptoms?
What is the next step in managing a 58-year-old female with a past medical history (PMHx) of Rheumatic Heart Disease (RHD), status post mechanical Mitral Valve Replacement (MVR) (2008) on Coumadin (warfarin), with Heart Failure with reduced Ejection Fraction (HFrEF) (Ejection Fraction (EF) 25%), Atrial Fibrillation (A-fib), asthma, Diabetes Mellitus (DM), anemia, varicose veins, and admitted with Acute Decompensated Heart Failure (ADHF), with laboratory results showing mild anemia (Hemoglobin (Hb) 9.9), elevated International Normalized Ratio (INR) 3.3, and elevated Pro-B-type Natriuretic Peptide (ProBNP) 9,349?
What are the functions of the posterior parietal lobe and what symptoms are expected with atrophy (patient)?
What is the likely cause of a 20-year-old male patient's symptoms of significant fatigue, weight gain, and cognitive problems, given abnormal endocrinology labs including elevated Iron Binding Capacity (Total Iron-Binding Capacity), Urinary Bile Conjugates (UBC) is not typically measured, possibly referring to Unsaturated Iron Binding Capacity (UIBC), low iron saturation, elevated Insulin-Like Growth Factor (IGF-1), and hypercortisolism?
Does a 53-year-old female patient with a pathological stage of pT3N0M0 (American Joint Committee on Cancer (AJCC) 8th edition) moderately differentiated adenocarcinoma (Grade 2) of the sigmoid colon require adjuvant chemotherapy?
What is the mode of action of Levamisole (antiparasitic medication)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.